Official PDF Translation•Acta Biochimica et Biophysica Sinica

SOX2 transactivates NRF2 to promote carboplatin resistance in lung squamous cell carcinoma

Authors: Hanfei Gao; Chaomei Li; Jie Sun; Liyuan Deng; Jia Li; Zhiqiang Wu; Hu Chen

DOI: 10.3724/abbs.2025228Status: Verified Translated Edition

Sponsored AdvertisementAd Placement Area

reCAPTCHA Bot Shield Active

Preparing Secure Academic Download

Verifying human reader & generating high-resolution document...

Verifying Document Integrity15s remaining

← Back to Article

Protected by Google reCAPTCHA v3.•Privacy•Terms

Sponsored ContentAdSense In-Feed Ad Slot

Key Findings in This Report

• SOX2 is highly expressed in LUSC and correlates with poor prognosis, driving carboplatin resistance. • SOX2 directly transactivates NRF2, enhancing glutathione synthesis to counteract carboplatin-induced oxidative stress. • Inhibition of NRF2, either pharmacologically or genetically, reverses SOX2-mediated carboplatin resistance in vitro and in vivo. • The SOX2-NRF2 axis is a promising therapeutic target; NRF2 inhibition could overcome chemoresistance in LUSC.